Analyses of sphingosine‐1‐phosphate in the context of transfusion: how much is in stored blood products and in patient blood?

Poppe, Annika; Moritz, Eileen; Geffken, Maria; Schreiber, Joerg; Greiwe, Gillis; Amschler, Katharina; Wruck, Marie-Louise; Schwedhelm, Edzard; Daum, Günter; Kluge, Stefan; Peine, Sven; Winkler, Martin Sebastian

doi:10.1111/trf.15494

Cited by 6 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Healthy controls were recruited from the Institute for Transfusion Medicine, as previously described. 11,12 ) were performed in the on state with medication. Comorbidities and laboratory parameters were recorded as previously described.…”

Section: Study Design Ethical Approval and Patient Consentmentioning

confidence: 99%

See 1 more Smart Citation

Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Treatment with sphingosine-1-phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD).Objectives: We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD. Methods: S1P concentrations were analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) in serum of 196 PD patients and in 196 age-and sex-matched controls. Motor (Unified Parkinson's disease rating scale III [UPDRS III], Hoehn and Yahr) and cognitive (Montreal Cognitive Assessment [MoCA]) function were assessed at baseline. Follow-up data was available from 64 patients (median [interquartile range], 513 [381-677] days). Results: S1P levels were lower in PD patients compared with controls, that is 1.75 (1.38-2.07) and 1.90 (1.59-2.18) μmol/L, respectively (P = 0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn and Yahr stage. In the follow-up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI, 1.98, 11.50]), but not with cognitive worsening. Conclusions: Our observations reveal an association of S1P with PD.

show abstract

Section: Study Design Ethical Approval and Patient Consentmentioning

confidence: 99%

“…Healthy controls were recruited from the Institute for Transfusion Medicine, as previously described. 11,12…”

Section: Study Design Ethical Approval and Patient Consentmentioning

confidence: 99%

Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…A concomitant increase in ceramides and decrease in sphinosine‐1‐phosphate suggests a shift in sphingolipid metabolism . Level of sphinosine‐1‐phosphate is maximum in freshly isolated platelet concentrates and decreases progressively during storage to 60% within 4 days . These observations may influence the choice of platelet concentrates for transfusion particularly in critically ill patients who show significantly reduced plasma levels of sphinosine‐1‐phosphate .…”

Section: Empowering Platelet Lipidomicsmentioning

confidence: 99%

“…Level of sphinosine‐1‐phosphate is maximum in freshly isolated platelet concentrates and decreases progressively during storage to 60% within 4 days . These observations may influence the choice of platelet concentrates for transfusion particularly in critically ill patients who show significantly reduced plasma levels of sphinosine‐1‐phosphate . Antiplatelet therapies also influence lipid metabolism.…”

Section: Empowering Platelet Lipidomicsmentioning

confidence: 99%

Platelet lipidome: Dismantling the “Trojan horse” in the bloodstream

Chatterjee

2020

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

The platelet‐lipid chapter in the story of atherothrombosis is an old one, recapitulated and revised in many contexts. For decades several stimulating facets have been added to it, both unraveling and increasing the perplexity of platelet‐lipid interplay and its pathophysiological consequences. The recent paradigm shift in our perspective has evolved with lipidomic analysis of the intraplatelet compartment and platelet releasate. These investigations have disclosed that platelets are in constant interaction with circulatory lipids, often reflected in their lipid repertoire. In addition, they offer a shielded intracellular space for oxidative lipid metabolism generating “toxic” metabolites that escape degradation by plasma lipases and antioxidant defense, circulate undetected by conventional plasma lipid profile, and deposited at atherosclerotic lesions or thrombus. Lipidomics divulges this silent invader in platelet vehicles, thereby providing potential biomarkers of pathologic manifestations and therapeutic targets to be exploited, which is surmised in this review.

show abstract

“…S1P levels are relatively higher in the blood than intracellularly; the concentration of serum S1P in healthy humans is approximately 1 μM [ 107 ]. S1P is stored in endothelial cells, erythrocytes, and thrombocytes [ 108 , 109 ].…”

Section: Sphingolipids In Ocular Neovascularizationmentioning

confidence: 99%

Lipid Signaling in Ocular Neovascularization

Terao

Kaneko

2020

IJMS

View full text Add to dashboard Cite

Vasculogenesis and angiogenesis play a crucial role in embryonic development. Pathological neovascularization in ocular tissues can lead to vision-threatening vascular diseases, including proliferative diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, choroidal neovascularization, and corneal neovascularization. Neovascularization involves various cellular processes and signaling pathways and is regulated by angiogenic factors such as vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF). Modulating these circuits may represent a promising strategy to treat ocular neovascular diseases. Lipid mediators derived from membrane lipids are abundantly present in most tissues and exert a wide range of biological functions by regulating various signaling pathways. In particular, glycerophospholipids, sphingolipids, and polyunsaturated fatty acids exert potent pro-angiogenic or anti-angiogenic effects, according to the findings of numerous preclinical and clinical studies. In this review, we summarize the current knowledge regarding the regulation of ocular neovascularization by lipid mediators and their metabolites. A better understanding of the effects of lipid signaling in neovascularization may provide novel therapeutic strategies to treat ocular neovascular diseases and other human disorders.

show abstract

Analyses of sphingosine‐1‐phosphate in the context of transfusion: how much is in stored blood products and in patient blood?

Cited by 6 publications

References 22 publications

Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)

Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)

Platelet lipidome: Dismantling the “Trojan horse” in the bloodstream

Lipid Signaling in Ocular Neovascularization

Contact Info

Product

Resources

About